Enfusion Inc [ENFN] stock is trading at $9.51, up 1.17%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ENFN shares have gain 3.59% over the last week, with a monthly amount glided 11.62%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Goldman downgraded its rating to Sell on February 28, 2024, and dropped its price target to $8. On January 30, 2024, downgrade downgraded it’s rating to Underweight and revised its price target to $9 on the stock. UBS started tracking the stock assigning a Neutral rating and suggested a price target of $9 on November 07, 2023. Piper Sandler initiated its recommendation with a Neutral and recommended $11 as its price target on April 03, 2023. JP Morgan started tracking with a Neutral rating for this stock on March 15, 2023, and assigned it a price target of $12. In a note dated January 04, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $15 to $10.
Enfusion Inc [ENFN] stock has fluctuated between $7.52 and $10.89 over the past year. Enfusion Inc [NYSE: ENFN] shares were valued at $9.51 at the most recent close of the market.
Analyzing the ENFN fundamentals
Enfusion Inc [NYSE:ENFN] reported sales of 181.62M for the trailing twelve months, which represents a growth of 17.28%. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at 0.03%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.01%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.05 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.37 points at the first support level, and at 9.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.63, and for the 2nd resistance point, it is at 9.76.
Ratios To Look Out For
For context, Enfusion Inc’s Current Ratio is 4.07. As well, the Quick Ratio is 4.07, while the Cash Ratio is 1.89. Considering the valuation of this stock, the price to sales ratio is 4.81, the price to book ratio is 14.72 and price to earnings (TTM) ratio is 470.79.
Transactions by insiders
Recent insider trading involved Bastone Bronwen, Chief People Officer, that happened on Jun 20 ’24 when 18241.0 shares were sold. Chief People Officer, Bastone Bronwen completed a deal on Jun 18 ’24 to sell 10539.0 shares. Meanwhile, General Counsel Campobasso Matthew sold 1651.0 shares on Jun 18 ’24.
